Venetoclax combined with low dose cytarabine compared to standard of care intensive chemotherapy for the treatment of favourable risk adult acute myeloid leukaemia (VICTOR): Study protocol for an international, open-label, multicentre, molecularly-guided randomised, phase II trial

Autor: Richard Dillon, Shanna Maycock, Aimee Jackson, Sonia Fox, Sylvie Freeman, Charles Craddock, Catherine Thomas, Emma Homer, Jane Leahy, Anna Mamwell, Nicola Potter, Nigel Russell, Andrew Wei, Hans Beier Ommen, Claire Hemmaway, Steve Knapper, Lucinda Billingham

Publikováno v: BMC Cancer, Vol 22, Iss 1, Pp 1-13 (2022)

Abstract Background For patients with acute myeloid leukaemia (AML), the only potentially curative treatment is intensive chemotherapy (IC). This is highly toxic, particularly for patients > 60 years, potentially leading to prolonged hospitalisations

Externí odkaz: https://doaj.org/article/41d5434bbabd4022946da909bc66c527

FLAG-Ida Combined with Gemtuzumab Ozogamicin (GO) Improves Event Free Survival in Younger Patients with Newly Diagnosed Acute Myeloid Leukaemia (AML) and Shows an Overall Survival Benefit in NPM1 and FLT3 mutated Subgroups. Results from the UK NCRI AML19 Trial

Autor: Nigel H. Russell, Charlotte Wilhelm-Benartzi, Steve Knapper, Leona M Batten, Joanna Canham, Emily L Hinson, Ulrik Malthe Overgaard, Amanda Gilkes, Jad Othman, Nicola Potter, Richard Dillon, Priyanka Mehta, Panagiotis Kottaridis, Jamie Cavenagh, Claire Hemmaway, Claire Arnold, Sylvie D Freeman, Mike Dennis

Publikováno v: Blood. 140:526-528

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::d403598a5c0a531f8142a9be4df0567d
https://doi.org/10.1182/blood-2022-162377

'I Don't Have to be Sick to Still Be Worthy': The Barriers Experienced by Adolescent and Young Adult Cancer Survivors in New Zealand

Autor: Tristan Pettit, Ellyn Proffit, Julia Reid, Hazel Dobinson, Val Waugh, Louise Sue, Tracey Vincent, Simone McMillan, Claire Hemmaway, Kate Kilpatrick, Eleanor Wilding, Heidi Watson, Kirsten Ballantine

Publikováno v: Journal of adolescent and young adult oncology.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::465ad59daf8601cdd80c56e596acfad1
https://pubmed.ncbi.nlm.nih.gov/35917507

Long-term efficacy, safety and neurotolerability of MATRix regimen followed by autologous transplant in primary CNS lymphoma: 7-year results of the IELSG32 randomized trial

Autor: Andrés J M, Ferreri, Kate, Cwynarski, Elisa, Pulczynski, Christopher P, Fox, Elisabeth, Schorb, Claudia, Celico, Monica, Falautano, Alessandro, Nonis, Paul, La Rosée, Mascia, Binder, Alberto, Fabbri, Fiorella, Ilariucci, Mauro, Krampera, Alexander, Roth, Claire, Hemmaway, Peter W, Johnson, Kim M, Linton, Tobias, Pukrop, Jettes Sønderskov, Gørløv, Monica, Balzarotti, Georg, Hess, Ulrich, Keller, Stephan, Stilgenbauer, Jense, Panse, Alessandra, Tucci, Lorella, Orsucci, Francesco, Pisani, Manuela, Zanni, Stefan W, Krause, Hans J, Schmoll, Bernd, Hertenstein, Mathias, Rummel, Jeffery, Smith, Lorenz, Thurner, Giuseppina, Cabras, Elsa, Pennese, Maurilio, Ponzoni, Martina, Deckert, Letterio S, Politi, Jurgen, Finke, Antonella, Ferranti, Kelly, Cozens, Elvira, Burger, Nicoletta, Ielmini, Franco, Cavalli, Emanuele, Zucca, Gerald, Illerhaus

Publikováno v: Ferreri, A J M, Cwynarski, K, Pulczynski, E, Fox, C P, Schorb, E, Celico, C, Falautano, M, Nonis, A, La Rosée, P, Binder, M, Fabbri, A, Ilariucci, F, Krampera, M, Roth, A, Hemmaway, C, Johnson, P W, Linton, K M, Pukrop, T, Gørløv, J S, Balzarotti, M, Hess, G, Keller, U, Stilgenbauer, S, Panse, J, Tucci, A, Orsucci, L, Pisani, F, Zanni, M, Krause, S W, Schmoll, H J, Hertenstein, B, Rummel, M, Smith, J, Thurner, L, Cabras, G, Pennese, E, Ponzoni, M, Deckert, M, Politi, L S, Finke, J, Ferranti, A, Cozens, K, Burger, E, Ielmini, N, Cavalli, F, Zucca, E, Illerhaus, G & IELSG32 study investigators 2022, ' Long-term efficacy, safety and neurotolerability of MATRix regimen followed by autologous transplant in primary CNS lymphoma : 7-year results of the IELSG32 randomized trial ', Leukemia, vol. 36, no. 7, pp. 1870-1878 . https://doi.org/10.1038/s41375-022-01582-5

219 HIV-negative adults ≤70 years with primary CNS lymphoma (PCNSL) were enrolled in the randomized IELSG32 trial. Enrolled patients were randomly assigned to receive methotrexate-cytarabine (arm A), or methotrexate-cytarabine-rituximab (B), or met

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ca71e062cac7ea0aa1bd288b51b3ad3b
https://pubmed.ncbi.nlm.nih.gov/35562406

The Natural History of NPM1MUT Measurable Residual Disease (MRD) Positivity after Completion of Chemotherapy in Acute Myeloid Leukemia (AML)

Autor: Nisha Thiagarajah, Richard Dillon, Nigel H. Russell, Amanda F. Gilkes, Ashish Bajel, Ing Soo Tiong, Andrew H. Wei, Claire Hemmaway, Abin Thomas, Nicola E. Potter, Matthew Smith, James Anton Kuzich, Chung H. Kok, Adam Ivey

Publikováno v: Blood. 136:25-27

Introduction Molecular MRD assays targeting NPM1 mutant (mut) transcripts have an established role for monitoring treatment efficacy in patients with NPM1mut AML. Approximately 25% of NPM1mut patients show persistent MRD level in the bone marrow (BM)

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::bfdce1d2846f0299fd9ee3362b121572
https://doi.org/10.1182/blood-2020-140296